Iovance Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Iovance Biotherapeutics Analyst Ratings
JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating
Iovance Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Iovance Biotherapeutics Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Iovance Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (IOVA) Gets a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating
Iovance Biotherapeutics Analyst Ratings
Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Analyst Ratings